Literature DB >> 3312026

[Comparative in vitro study of the antimicrobial activity of ceftazidime against clinical isolates].

W Klietmann1, J Focht, K Nösner.   

Abstract

The antimicrobial activity of ceftazidime was tested against 1482 gram-negative and 1216 gram-positive strains isolated from fresh clinical specimens and compared with generally used antibiotics including other third generation cephalosporins and broad spectrum penicillins. Minimal inhibitory concentrations were determined in a broth dilution test on microtiter plates. In the group of the gram-negative bacteria ceftazidime was the most active of the antimicrobial agents tested with an MIC of 0.5 mg/l (MIC90) for most of the isolates. Ceftazidime exhibited a broad spectrum of activity against gram-negative pathogenic bacteria including Enterobacteriaceae (Escherichia coli, Klebsiella spp., Proteus spp. Enterobacter spp., Citrobacter spp., Serratia spp.) including frequently resistant strains of Pseudomonas aeruginosa, Acinetobacter spp. and Alcaligenes faecalis. The activity against P. aeruginosa is the most remarkable property of the agent. Ceftazidime is less effective against gram-positive compared to gram-negative bacteria. No inhibitory action can be observed against Streptococcus faecalis.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3312026     DOI: 10.1007/BF01645861

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  10 in total

1.  The pharmacy of ceftazidime.

Authors:  B L Richardson; J D Woodford; G D Andrews
Journal:  J Antimicrob Chemother       Date:  1981-09       Impact factor: 5.790

2.  Comparison of the in-vitro activities of ceftazidime and new cephalosporins against 107 strains of Pseudomonas aeruginosa and 249 strains of cefazolin-resistant Enterobacteriaceae.

Authors:  A Thabaut; J L Durosoir; P Saliou
Journal:  J Antimicrob Chemother       Date:  1981-09       Impact factor: 5.790

3.  Ceftazidime in cystic fibrosis.

Authors:  B Gordts; I Dab; J P Butzler
Journal:  Lancet       Date:  1982-06-12       Impact factor: 79.321

4.  [Synergistic activity between ticarcillin, azlocillin, cefsulodin, ceftazidime and tobramycin or amikacin against Pseudomonas aeruginosa (author's transl)].

Authors:  J C Petit; G Richard; B Burghoffer; G L Daguet
Journal:  Pathol Biol (Paris)       Date:  1982-06

5.  In-vitro activity of augmentin against clinically important gram-positive and gram-negative bacteria in comparison with other antibiotics.

Authors:  J Focht; W Klietmann; H D Heilmann
Journal:  Zentralbl Bakteriol Mikrobiol Hyg A       Date:  1984-04

6.  Sensitivity of enterococci to beta-lactam antibiotics, co-trimoxazole, nitrofurantoin, tetracycline and doxycycline.

Authors:  H Grimm
Journal:  Arzneimittelforschung       Date:  1983

7.  In-vitro activity of ceftazidime, a beta-lactamase stable cephalosporin.

Authors:  H C Neu
Journal:  J Antimicrob Chemother       Date:  1981-09       Impact factor: 5.790

8.  Pharmacokinetics and bacteriological effect of ceftazidime in experimental Streptococcus pneumoniae, Haemophilus influenzae, and Escherichia coli meningitis.

Authors:  Y Sakata; A Boccazzi; G H McCracken
Journal:  Antimicrob Agents Chemother       Date:  1983-02       Impact factor: 5.191

9.  Ceftazidime: in-vitro antibacterial activity and susceptibility to beta-lactamases compared with that of cefotaxime, moxalactam and other beta-lactam antibiotics.

Authors:  I Phillips; C Warren; K Shannon; A King; D Hanslo
Journal:  J Antimicrob Chemother       Date:  1981-09       Impact factor: 5.790

10.  In vitro comparative activity of moxalactam, GR 20263, and N-formimidoyl thienamycin to other beta-lactam antibiotics and tobramycin against enterobacteriaceae and staphylococci.

Authors:  M H Cynamon; P A Granato
Journal:  Chemotherapy       Date:  1982       Impact factor: 2.544

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.